ClinicalTrials.gg
WithdrawnNCT05176691Updated Feb 21, 2023

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

A Phase 1 interventional study of HMPL-760 in CLL/SLL, NHL and MCL, sponsored by Hutchmed. Withdrawn at 36 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Why this study was withdrawn
HUTCHMED has decided to discontinue the HMPL 760 study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States — 57 open to participants now, 95 under way, 6 of them phase 3. Lymphoma, B-Cell, Marginal Zone · United States.

Enrollment
539th of 557
0 · median 36
Started
2022
with 10 others
Phase 1
247 of 674
22 open now
Registered
619th of 674
by date

Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, this one is the 539th largest by enrollment of the 557 interventional ones that give a count, is one of 11 that started in 2022, is one of 247 in phase 1, and was the 619th registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

57 of the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, or all of them as a file.
02

Study summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

Read the detailed description

HMPL-760 is a highly potent, selective, and reversible inhibitor against BTK, which would be studied in B-cell malignancy carrying either BTK(WT) or BTK(C481S).

This is a phase 1, open-label, multicenter, single-arm study to evaluate safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL

The study consists of 2 parts:

Part 1- Dose Escalation to determine MTD and/or RP2D of HMPL-760

Part 2- Dose Expansion to characterize the safety and tolerability of HMPL-760

03

Conditions studied

  • CLL/SLL
  • NHL
  • MCL
  • MZL
  • Lymphoplasmacytic Lymphoma
  • Waldenstrom Macroglobulinemia
  • Follicular Lymphoma
  • DLBCL
  • Richter Syndrome

Keywords

  • Lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia
  • Chronic lymphocytic leukemia
  • Non-Hodgkin lymphoma
  • Mantle cell lymphoma
  • Marginal zone lymphoma
  • Follicular lymphoma
  • Diffuse large B-cell lymphoma
  • BTK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of 0 or 1;
  • confirmed NHL or CLL with disease progression or intolerance to either ≥2 prior regimens. Patients with CLL/SLL and indolent NHL must meet criteria for systemic therapy. Patients with gastric extranodal MZL who are H. pylori positive must have failed H. pylori eradication therapy.
  • Availability of tumor sample: This may be an sample obtained after most recent therapy or a fresh biopsy; if tumor sample is not available for patients in dose escalation, the Sponsor may waive the requirement after discussion.
  • Dose expansion stage only: Patients must have been treated with 1 prior regimen containing a BTK inhibitor in cohorts 1 to 5;
  • Expected survival of more than 24 weeks as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Patients with primary central nervous system lymphoma.
  • Any of the following laboratory abnormalities:

    • (ANC) \<0.75×109/L
    • \<8 mg/L
    • \<50×109/L
    • Note: In the dose expansion stage, patients with cell counts below the thresholds listed above may be considered eligible if there is documented bone marrow infiltration and Sponsor approval
  • Inadequate organ function
  • (INR) >1.5×, activated partial thromboplastin time (aPTT) >1.5×ULN

    • Patients requiring anticoagulation therapy (except vitamin K antagonists [ie, warfarin]) but with a stable INR within the recommended range according to the local guideline are eligible.
  • Patients with presence of second primary malignant tumors within the last 2 years, with the exception of the following:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
  • history of liver disease, including cirrhosis or current known active infection with (HIV), virus (HBV), virus (HCV), or cytomegalovirus (CMV).
  • Cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, vaccine, or radiotherapy within 3 weeks prior to initiation of study treatment. For oral targeted therapies, a of 5 half-lives of the agent (minimum 3 days) prior to the initiation of study treatment can be used.
  • Any granulocyte colony-stimulating factor treatment/blood transfusion within 7 days before the screening hematology test.
  • Prior use of any drug that is a strong inducer or inhibitor of within 2 weeks prior to initiation of study treatment.
  • Prior use of proton pump inhibitors (PPIs) within 5 days of study treatment
  • Any transplant within 100 days prior to initiation of study treatment
  • Clinically significant active infection or with an unexplained fever.
  • Treatment within a clinical study of an agent or using an investigational device within 3 weeks prior to initiation of the current study treatment.
  • AEs from prior antineoplastic therapy that have not resolved to grade \<1
  • Pregnant (positive urine or serum beta human chorionic gonadotropin test) or lactating women.
  • New Your Heart Association () class II or greater congestive heart failure.

NOTE: Only key inclusion/exclusion criteria are listed. Full details are in the protocol.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment

    All patients to receive HMPL-760 daily.

    Drug: HMPL-760

Interventions

  • Administered orally QD for 28-day cycles

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    Adverse event (AE) that meets protocol defined DLT criteria during dose escalation

    Time frame: Up to 28 days after first dose of study drug

  2. Incidence of AEs/SAEs

    Any untoward medical occurrence associated with the use of study drug

    Time frame: From 1st dose to within 30 days of last dose

  3. MTD

    To evaluate maximum tolerated dose of HMPL-760 in subjects, if reached

    Time frame: From 1st dose to within 30 days of last dose

  4. RP2D

    To determine recommended phase 2 dose of HMPL-760 in subjects

    Time frame: From 1st dose to within 30 days of last dose

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of subjects achieving partial response and better response during the study

    Time frame: From 1st dose of study drug to the time of progressive disease, assessed up to 36 months

  2. Duration of Response (DoR)

    DoR is defined as the time between the initial response to therapy and subsequent disease progression or relapse.

    Time frame: From first dose of study drug to the time of progressive disease, assessed up to 36 months

  3. Clinical Benefit Rate (CBR)

    CBR is defined as the proportion of subjects achieving objective response or stable disease

    Time frame: From 1st dose of study drug to the time of progressive disease, assessed up to 36 months

  4. Progression-free Survival (PFS)

    PFS is defined as survival without progression of the disease

    Time frame: From 1st dose of study drug to the time of progressive disease, assessed up to 36 months

  5. Maximum Plasma Concentration [Cmax]

    To determine the maximum observed plasma concentration of HMPL-760

    Time frame: From 1st dose to within 30 days of last dose

  6. Chemokines

    To observe blood plasma concentrations of chemokines such as CCL22 and CCL3

    Time frame: From 1st dose to within 30 days of last dose

  7. Phospho-BTK

    To observe the whole blood concentrations of phospho-BTK

    Time frame: From 1st dose to within 30 days of last dose

07

Study locations

36 sites
  • Innovative Clinical Research
    Anaheim, California 92801, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Tulane Cancer Center
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Clinical Research Center
    Baltimore, Maryland 21287, United States
  • AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company
    Kansas City, Missouri 64114, United States
  • Center For Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • New York University Langone Med Center. Lab
    New York, New York 10016, United States
  • Clinical Research Alliance
    Westbury, New York 11590, United States
  • Renovatio Clinical
    El Paso, Texas 79915, United States
  • Oncology Consultants, P.A.
    Houston, Texas 77030, United States
  • Renovatio Clinical
    The Woodlands, Texas 79915, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Centre Antoine Lacassagne
    Nice, Alpes Maritimes 6200, France
  • Hôpital Saint-Antoine
    Paris cedex 12, Paris 7551, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris cedex 13, Paris 75651, France
  • Institut Gustave Roussy
    Villejuif cedex, Val De Marne 94805, France
  • CHU Poitiers - Hôpital la Milétrie
    Poitiers, Vienne 86021, France
  • Hadassah University Hospital - Ein Kerem
    Jerusalem, 9112001, Israel
  • Rabin Medical Center-Beilinson Campus
    Petach-Tikva, 4941492, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5262001, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Lazio, Roma 168, Italy
  • Fondazione del Piemonte per l'Oncologia IRCC Candiolo
    Candiolo, Torino 10060, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
    Bologna, 40138, Italy
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
  • Wojewodzki Szpital Specjalistyczny w Legnicy
    Legnica, 59-220, Poland
  • Centrum Medyczne Pratia Poznan
    Skórzewo, 60-185, Poland
  • MICS Centrum Medyczne Torun
    Toruń, 87-100, Poland
  • ICO l'Hospitalet - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barcelona 8908, Spain
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Sevilla 41010, Spain
  • Hospital del Mar
    Barcelona, 8003, Spain
  • MD Anderson Cancer Centre
    Madrid, 28033, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Nov 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Jan 4, 2022
StartActual
Feb 15, 2022
Primary completionActual
Nov 16, 2022
CompletionActual
Nov 16, 2022
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05176691
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Feb 15, 2022
Primary completion
Nov 16, 2022
Completion
Nov 16, 2022
Last update
Feb 21, 2023

Study contacts

Vijay Jayaprakash, MBBS, PHD
study director · Hutchison Medipharma Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor HMPL-760

Start the discussion